GlassScriptPhysician profile
Breanna Johnson
NPI 1760077093
$2,191.01
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $600 · 2023: $1,486 · 2024: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $394.48 | 2022-2024 | Rexulti, Abilify Maintena |
| Abbvie INC. | $321.03 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.72 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.99 | 2022-2023 | Jardiance |
| Novo Nordisk INC | $151.27 | 2022-2023 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $105.39 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.27 | 2022-2023 | Trulance, Xifaxan |
| Novartis Pharmaceuticals Corporation | $78.57 | 2022-2023 | |
| Abbott Laboratories | $77.94 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $69.82 | 2022-2023 | Trintellix |
| Paratek Pharmaceuticals, INC. | $58.97 | 2023 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $51.58 | 2022-2023 | Farxiga |
| Idorsia Pharmaceuticals US INC | $51.38 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $50.15 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $47.33 | 2023 | Dificid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $35.17 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $35.01 | 2022-2023 | Livalo, Seglentis |
| Esperion Therapeutics, INC. | $30.41 | 2022-2023 | Nexletol |
| Medtronic, INC. | $27.78 | 2024 | Onyx Frontier |
| Daiichi Sankyo INC. | $21.48 | 2023 | Injectafer |
| Boston Scientific Corporation | $19.11 | 2023 | |
| Corcept Therapeutics | $16.94 | 2023 | Korlym |
| Mycovia Pharmaceuticals, INC. | $15.43 | 2023 | Vivjoa |
| Lilly USA, LLC | $14.93 | 2023 | Mounjaro |
| Fidia Pharma USA INC. | $14.55 | 2023 | Triluron, Hymovis |
| Janssen Pharmaceuticals, INC | $13.64 | 2022 | |
| Axsome Therapeutics, INC. | $12.90 | 2022 | |
| Mylan Specialty L.P. | $12.77 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breanna Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.